(Photo Credit - Nick Youngson)
Intec Pharma Ltd. (NASDAQ:NTEC), an Israeli-based clinical stage biotechnology / pharmaceutical company, just announced the appointment of Jeffrey A. Meckler as the company's new Chief Executive Officer, effective immediately.
Meckler was named Vice Chairman of the Intec Pharma Board of Directors in April 2017 and will continue in that role. Giora Carni, a Director since 2006 who was serving Intec as Interim Chief Executive Officer since May 2017, will continue to serve on the company's Board of Directors.
Now Read: 8 Marijuana Stocks Trading on the Nasdaq Exchange
"In the few months Jeffrey has been on the Intec Board he established himself as a strong, insightful leader and made significant contributions to our company. We are delighted to appoint him as Chief Executive Officer and extend thanks to Giora for stepping in to serve as interim CEO," commented John W. Kozarich, Ph.D., Chairman of the Board of Intech Pharma.
"We look forward to building a U.S. presence under Jeffrey's stewardship while advancing our Accordion Pill platform technology in a number of therapeutic indications. In particular, as we near the completion of a pivotal Phase 3 clinical trial of our Accordion Pill Carbidopa/Levodopa, Jeffrey's considerable industry experience should enhance our pre-commercialization strategies to maximize the potential of the Accordion Pill in Parkinson's disease," he added. "Importantly, Jeffrey's strategic planning and business development skills make him uniquely qualified to expand our platform technology in various indications and to enhance the industry's recognition of our gastric retention drug delivery technology."
Now Read: Inside Intec Pharma's Accordion Pill Technology
Meckler has more than 25 years of executive experience in the biotechnology and life sciences space. With more than 17 years of experience at Pfizer (NYSE:PFE), it is no doubt that Meckler will bring top-notch management skills to Intec Pharma. Most recently, Meckler was CEO of Cocrystal Pharma, Inc. (OTC:COCP).
"I am honored to be named CEO of Intec Pharma at this pivotal point in our company's development," said Mr. Meckler. "We face significant opportunities with our late-stage program in Parkinson's disease. In addition we have a versatile platform technology that can improve the efficacy and safety of existing and development-stage drugs by utilizing a proprietary gastric retention mechanism. I look forward to working with our team in Israel and to establishing a footprint in the U.S. Together we will execute a broad development program for the Accordion Pill technology that will allow us to build value for our shareholders and ensure the success of our company."
Now Read: Trading Marijuana Stock Commission-Free Through Robinhood
For more information on Intec Pharma Ltd., be sure to check out the company's profile in our comprehensive marijuana stocks database. Subscribe to one or more of our free e-mail newsletters so you never miss an important cannabis stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, and Instagram.